58 results about "Hypertensive disorder" patented technology

Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity.

The present invention provides methods and compositions related to the detection and / or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and / or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.

Food products fortified with a therapeutically effective amount of milk mineral are administered for the treatment of high blood pressure, stroke, obesity, kidney stones, colon cancer, breast cancer, head and neck tumors, premenstrual syndrome, postpartum depression, hypertensive disorders of pregnancy, Type-2 diabetes, depression, asthma, inflammatory bowel disease, attention deficit disorder, migraine headaches, kidney disease, hypercholesterolaemia, congestive heart failure, or immune deficiency.

The invention relates to screening methods for determination of the risk of preterm delivery and / or pregnancy associated conditions. The methods involve detection of the level of one or more biomarkers in a biological sample from the patient. In particular, in embodiments of the invention there are provided methods for determining the risk of pre-eclampsia and other hypertensive disorders, and intrauterine growth retardation (IGUR).

The application discloses new test panels comprising biomarkers and clinical parameters, for the prediction, diagnosis, prognosis and / or monitoring of hypertensive disorders of pregnancy and particularly preeclampsia; and related methods, uses, kits and devices.

Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium / calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sF1t-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that increase endothelial nitric oxide synthase levels or biological activity.

A system and method for treating hypertension and other medical disorders is provided. The system utilizes data collection devices for monitoring medical parameters of a plurality of patients and collecting data related to the medical parameters, and a centralized database for storing the collected data for each of the plurality of patients. Input devices are also used for transferring patient information such as name, family history, medications, weight, age, etc. to the database. The database correlates the collected data to the patient information for purposes of treatment and later retrieval by users to carry out research and other activities in which the collected data and patient information is useful. The system and method is particularly adapted for diagnosing and treating maternal hypertensive disorders such as preeclampsia and carrying out research related to understanding preeclampsia.

The present invention discloses methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin, endothelial nitric oxide synthase, PGI2, TGF-betal, TGF-beta3, activin A, BMP2, BMP7, and sFlt-1 expression levels or biological activity. Also disclosed are methods of diagnosing a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, that include the measurement of any one or more of the following: soluble endoglin, endothelial nitric oxide synthase, PGI2, TGF-betal, TGF-beta3, activin A, BMP2, BMP7, and sFlt-1 expression levels or biological activity.

The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin.

The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and / or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and / or performing said methods.

The application discloses new test panels comprising biomarkers and clinical parameters, for the prediction, diagnosis, prognosis and / or monitoring of hypertensive disorders of pregnancy and particularly preeclampsia; and related methods, uses, kits and devices.

A system for monitoring a fetus in a pregnant woman, and / or the maternal health risk for pregnancies complicated by such as pre-eclampsia and hypertensive disorders is configured to be worn by the pregnant woman, preferably so as to allow monitoring during daily life, e.g. in the form of an adhesive patch. The unit has a sound sensor, e.g. a microphone or accelerometer, to be positioned on the skin of the abdominal area so as to detect a vascular sound from umbilical arteries of the fetus or from the uterine arteries of the pregnant woman. The sound sensor is functionally connected to a processing unit which executes a processing algorithm on the captured vascular sound and extracts a signal parameter accordingly. The processing unit then communicates the signal parameter, e.g. using an audio signal, a visual display or by means of a wired or a wireless data signal.

A method for the early prediction of risk of hypertensive disorders in pregnant women, including for example eclampsia, mild pre-eclampsia, chronic hypertension, EPH gestosis, gestational hypertension, superimposed pre-eclampsia, HELLP syndrome, or nephropathy.

The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

The invention relates to a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery comprising a pharmaceutically acceptable base and an effective amount of at least one cannabinoid or endocannabinoid containing extract of a cloned hybrid of the plant Cannabis sativa, subspecies sativa and Cannabis sativa, subspecies indica of the CTSX-ISS lineage; and methods of treatment of primary and secondary hypertension, the secondary hypertension resulting from pheochromocytoma, primary hyperaldosteronism, adrenal hyperplasia, pulmonary hypertension, portal hypertension, folate deficiency hypertension, arterial hypertension or familial hypertension by administration between one and eight times per day.

A hypertensive disorder expert system comprises a blood pressure gauge module, a patient information writing module, an expert database module, a recommendation display module, and a wireless transmitting module. The data output end of the blood pressure gauge module and the data output end of the patient information writing module are connected with the data input end of the expert database module; the data output end of the expert database module is connected with the data input end of the recommendation display module and the data input end of the wireless transmitting module. According to the hypertensive disorder expert system, fluctuation of blood pressure is measured for a patient three to four times regularly each day, a special treatment scheme is made for the patient through an expert database according to the age, sex and other symptoms, medicines are reasonably allocated for use, and real-time recommendations are provided for the patient with hypertensive disorders to control the blood pressure.

The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin.

The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

The invention provides traditional Chinese medicine for efficiently treating hypertension and a preparation method thereof, and relates to the technical field of drugs for treating hypertension. The traditional Chinese medicine is characterized in that the composition comprises the following components: 10-30 g of eucommia, 5-10 g of pangolin scales, 20-40 g of dipsacus root, 10-30 g of cornus officinalis sieb et zucc, 5-15 g of uncaria, 5-15 g of gastrodia elata, 40-60 g of astragali radix, 20-40 g of puerarin, 15-25 g of salviae miltiorrhizae, 20-40 g of medlar and 20-40 g of radix ophiopogonis. The preparation method comprises the following steps: soaking the drugs for 30 minutes to 1 hour, cooking the drugs at a big fire and cooking the drugs at a slow fire for about 30 minutes; pouring the cooked decoction, adding water in the drugs, boiling and cooking the drugs at slow fire for 30 minutes, mixing the decoction obtained at twice, and taking the same in twice. The traditional Chinese medicine disclosed by the invention can be used for treating hypertensive disorders, reducing the occurrence rate and death rate of heart and cerebral vessels to the maximum and prolonging the life of patients, and is good in drug properties, good in safety, pure natural, free of pollution and free of side effect.

The invention discloses a medicine for external use for treating hypertensive disorder, which is coated in a medicine bag. The raw materials in the medicine bag in parts by weight are as follows: 1-5 parts of Codonopsis pilosula, 1-5 parts of fried Rhizoma Atractylodis Macrocephalae, 1.5-7.5 parts of Astragalus mongholicus, 1.5-7.5 parts of prepared rehmannia root, 1-5 parts of dogwood, 1-5 parts of moutan bark, 1-5 parts of Poria cocos, 1-5 parts of rhizoma alismatis, 1-5 parts of the fruit of Chinese wolfberry, 0.5-3 parts of chrysanthemum, 1-5 parts of the root of red-rooted salvia, 0.5-3 parts of the root of bidentate achyranthes, 1.5-7.5 parts of concha haliotidis, 1-5 parts of fried semen cassiae, 1-5 parts of uncaria, 0.5-3 parts of radix paeoniae alba, 1-5 parts of fructus ligustri lucidi, 1-5 parts of Eclipta alba, 0.5-3 parts of selfheal and 0.5-3 parts of liquorice. The medicine acts on umbilical region of human body and is slowly released by using body temperature and absorbed by human organs to achieve the purpose of adjusting and stabilizing blood pressure, thereby avoiding damage to human body by orally taken hypotensive medicines thoroughly.

The present invention relates to the use of a steroid in the manufacture of a pharmaceutical composition for use in the therapeutic or prophylactic treatment of a hypertensive disorder of pregnancy (HDP) or fetal growth retardation, said treatment comprising administering to a female mammal a steroid selected from the group consisting of: substances represented by the following formula (formula I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1 - 5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors of such substances; and mixtures of one or more of the aforementioned substances and / or precursors.

The invention discloses a preparation method and an application of a mouse syncytiotrophoblast microvillous membrane. The preparation method comprises the following steps of: based on mouse placenta as a raw material, separating and enriching the mouse syncytiotrophoblast microvillous membrane by mechanical separation and improved differential centrifugation methods; detecting the concentration by protein concentration quantification and identifying and quantitatively marking by polypeptide antigens of tissues. The invention further discloses the application of the mouse syncytiotrophoblast microvillous membrane prepared by the preparation method in building a mouse model with hypertensive disorder complicating pregnancy. The mouse syncytiotrophoblast microvillous membrane prepared by the method disclosed by the invention is large in yield and high in concentration, and is highly similar to human syncytiotrophoblast microvillous membrane in shape and protein marker. The mouse syncytiotrophoblast microvillous membrane can be directly used to research occurrence and development mechanism of hypertensive disorder complicating pregnancy such as preeclampsia and eclampsia as well as medical base and clinical research for developing antagonistic medicines, and can be further used to prepare an animal model of hypertensive disorder complicating pregnancy.

The invention provides edible salt for children and pregnant women and a preparation method thereof. The content of sodium chloride in the edible salt is less than or equal to 73.8%, and the edible salt is prepared from milk mineral salt, resistant dextrin and potassium chloride. According to the edible salt for the children and pregnant women provided by the invention, milk mineral salt is takenas carbon source, low sodium salt is adopted for design, the addition amount of sodium chloride is effectively reduced and the usage of sodium chloride is reduced by 26.2% or above than that of commonedible salt by adding potassium chloride component, hypertensive disorder complicating pregnancy can be effectively reduced, sodium acceptable daily intake of children is reduced. The edible salt forchildren and pregnant women is rich in water-soluble dietary fiber, maintain intestinal health and relieve constipation during pregnancy, takes iodized salt as base material to supplement iodine elements needed for pregnancy and children's growth.